Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIASPAN vs NICOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL, and increases HDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and reducing hepatic triglyceride synthesis. It also decreases the catabolism of HDL apolipoproteins A-I and A-II.
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and decreasing free fatty acid mobilization from adipose tissue via activation of GPR109A (HM74A) receptor, leading to reduced triglyceride and LDL cholesterol synthesis. It also raises HDL cholesterol by decreasing hepatic clearance of apo A-I.
Primary dyslipidemia and mixed dyslipidemia as an adjunct to diet,Hypertriglyceridemia in patients at risk of pancreatitis,Reduction of risk of myocardial infarction in patients with hyperlipidemia and history of MI,Secondary prevention of cardiovascular events in combination with statin,Off-label: Prevention of pellagra (niacin deficiency)
Treatment of primary hyperlipidemia and mixed dyslipidemia (Fredrickson Types IIa and IIb),Reduction of risk of recurrent myocardial infarction in patients with prior MI and hyperlipidemia,Regression of coronary atherosclerosis (with bile acid sequestrant),Adjunct to diet in patients with elevated triglycerides (Types IV and V)
Starting dose: 500 mg orally once daily at bedtime; after 4 weeks, increase to 1000 mg once daily; then titrate to maintenance dose of 1500-2000 mg once daily; maximum dose: 2000 mg/day.
NICOLAR (niacin extended-release) is typically initiated at 500 mg orally once daily at bedtime, after a low-fat snack. The dose is increased by 500 mg every 4 weeks as tolerated, up to a maximum of 2000 mg once daily.
Terminal half-life is 20-45 minutes (immediate-release) but due to prolonged release formulation of Niaspan, the half-life is extended to 2-4 hours for total nicotinic acid and 12 hours for nicotinuric acid, allowing once-daily dosing.
Terminal elimination half-life is 14-24 hours in adults with normal renal function; clinically, this supports twice-daily dosing. In moderate renal impairment (Cr Cl 30-59 m L/min), half-life extends to 24-36 hours, requiring dose adjustment.
Primarily hepatic metabolism via two pathways: conjugation with glycine to form nicotinuric acid (major pathway, saturable) and conversion to nicotinamide adenine dinucleotide (NAD). Minor metabolism via oxidation to N-methylnicotinamide and other metabolites.
Extensively metabolized in the liver via two pathways: conjugation with glycine (major) to form nicotinuric acid, and N-methylation to N-methylnicotinamide. Also undergoes oxidation to nicotinamide N-oxide. CYP2E1 may be involved in some metabolic steps.
Primarily renal (60-76% as unchanged drug and metabolites). Hepatic metabolism is extensive; less than 2% excreted in feces.
Primarily renal (60-70% as unchanged drug and metabolites), with 10-20% biliary/fecal. Hepatic metabolism to inactive metabolites accounts for ~30% of elimination.
<20% bound to plasma proteins (mainly albumin). Binding is negligible at therapeutic concentrations.
Approximately 90% bound to human serum albumin, primarily to albumin and to a lesser extent to alpha-1-acid glycoprotein.
Approximately 0.5 L/kg (around 35 L in a 70 kg adult), indicating distribution into total body water.
Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution and high extravascular penetration, particularly into the respiratory tract.
Oral (extended-release): ~60-76% due to extensive first-pass metabolism. Bioavailability is dose-dependent and saturable at higher doses.
Oral: 30-60% due to first-pass metabolism. Inhaled: 10-20% reaching systemic circulation (majority acts locally with high lung deposition).
No specific dose adjustment provided by manufacturer; use with caution in patients with renal impairment; avoid in patients with severe renal impairment or nephrotic syndrome.
For patients with GFR <30 m L/min, reduce maximum dose to 1000 mg once daily due to increased risk of toxicity. For GFR 30-60 m L/min, no dose adjustment is required but monitor closely. No specific guidelines for dialysis.
Contraindicated in patients with significant or unexplained hepatic dysfunction; use with caution in patients with Child-Pugh class A, avoid in Child-Pugh class B or C.
Contraindicated in patients with Child-Pugh class B or C cirrhosis. For Child-Pugh class A (mild impairment), initiate at 500 mg once daily and titrate cautiously, with maximum dose not exceeding 1000 mg once daily. Monitor liver function tests frequently.
Safety and efficacy not established in pediatric patients; not recommended for use.
Not approved for use in pediatric patients below 16 years of age for dyslipidemia. Safety and efficacy have not been established.
No specific dose adjustment recommended; monitor for adverse effects such as myopathy and hepatotoxicity; initiate at low end of dosing range.
No specific dose adjustment is recommended solely based on age. However, elderly patients may have reduced renal function and increased risk of adverse effects (e.g., flushing, hyperglycemia). Initiate at the lowest starting dose (500 mg once daily) and titrate slowly. Monitor renal function and metabolic parameters closely.
No FDA black box warning.
Severe hepatotoxicity, including fulminant hepatic necrosis, has occurred with sustained-release formulations. Do not substitute for equivalent doses of immediate-release niacin.
Hepatotoxicity: elevated liver enzymes, rare severe hepatotoxicity; avoid in patients with active liver disease,Flushing: prostaglandin-mediated, can be reduced by taking aspirin or starting with low doses,Hyperglycemia: may increase blood glucose, use with caution in diabetic patients,Hyperuricemia: may precipitate gout, monitor uric acid,Gastrointestinal effects: can cause peptic ulcer, use caution with history of GI bleeding,Cardiovascular: may cause hypotension, especially with concurrent use of antihypertensives
Hepatotoxicity: Monitor liver function tests; discontinue if persistent elevations or signs of hepatic injury.,Hyperuricemia and gout: May increase uric acid levels; use with caution in patients predisposed to gout.,Peptic ulcer: Niacin may reactivate or exacerbate peptic ulcer disease.,Facial flushing (prostaglandin-mediated): To reduce, take with aspirin 30 minutes prior, or use extended-release formulations.,Increased bleeding risk when used with anticoagulants.,Monitor glucose levels in diabetic patients; niacin may impair glucose tolerance.
Active liver disease or unexplained transaminase elevations,Active peptic ulcer disease,Arterial bleeding,Hypersensitivity to niacin or any component of the formulation
Active liver disease or unexplained persistent transaminase elevations,Active peptic ulcer disease,Arterial bleeding,Hypersensitivity to niacin or any component,Lactation (relative contraindication)
Avoid alcohol, hot beverages, and spicy foods near dose time as they can worsen flushing. Take with a low-fat snack (e.g., apple, rice cakes) to reduce gastrointestinal upset and flushing. Avoid high-fat meals which may increase risk of flushing. Grapefruit juice has no significant interaction but other fruit juices have not been studied; advise moderate intake.
Avoid high-fat meals with the dose, as they may increase the risk of flushing. Alcohol and hot beverages should be avoided close to dosing, as they can exacerbate flushing. Grapefruit juice has no significant interaction. Maintain a consistent diet to avoid fluctuations in blood glucose.
Niacin (NIASPAN) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects at high doses, but there are no adequate and well-controlled studies in pregnant women. Niacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is no evidence of teratogenicity in humans at recommended doses, but high doses may cause fetal harm.
NICOLAR (niacin) is classified as FDA Pregnancy Category C. Adverse effects have been observed in animal reproduction studies, but no adequate human studies exist. First trimester: potential risk based on animal data; use only if benefit outweighs risk. Second and third trimesters: no known specific risks but limited data; avoid high doses due to possible maternal hepatotoxicity and hyperglycemia.
Niacin is excreted in human breast milk in amounts that are likely comparable to maternal plasma levels. The milk-to-plasma (M/P) ratio for niacin is approximately 1.0. The American Academy of Pediatrics considers niacin compatible with breastfeeding at usual dietary intakes, but high pharmacological doses should be avoided due to potential adverse effects in the infant, such as flushing and gastrointestinal disturbances.
Niacin is excreted into breast milk; M/P ratio not reported. Concentrations are low but caution is advised due to potential for high doses to cause adverse effects in the infant. Monitor infant for flushing, GI upset, or hepatotoxicity.
No specific dose adjustments are recommended for niacin during pregnancy due to lack of data on pharmacokinetic changes. However, doses should be kept at the lowest effective level and used only when clearly needed. There is no evidence that pregnancy alters niacin clearance or requires dose modification.
No specific dose adjustments are recommended for pregnancy; however, due to increased plasma volume and clearance, therapeutic efficacy may require monitoring. Use the lowest effective dose and monitor clinical response. Avoid extended-release formulations due to higher hepatotoxicity risk.
Niacin extended-release (NIASPAN) causes flushing, which can be mitigated by taking aspirin 30 minutes before dosing, avoiding alcohol and hot beverages at time of dosing, and initiating at low dose with gradual titration. Liver function tests must be monitored; elevation >3x ULN requires discontinuation. NIASPAN can exacerbate gout by increasing uric acid levels; check uric acid at baseline and periodically. Use with caution in diabetes as it may increase glucose levels. Avoid in patients with active liver disease, unexplained transaminase elevations, or peptic ulcer disease.
NICOLAR is a brand name for niacin (nicotinic acid) extended-release. Doses should be taken at bedtime with a low-fat snack to reduce flushing. Avoid concomitant use with statins due to increased risk of myopathy. Monitor liver function tests and blood glucose regularly. Aspirin 325 mg taken 30 minutes prior can mitigate flushing.
Take NIASPAN at bedtime with a low-fat snack to reduce flushing.,Do not take on an empty stomach; avoid alcohol and hot drinks near dose time.,Flushing may occur but usually decreases over weeks; can take aspirin 30 minutes prior to dose.,Do not miss doses; if a dose is missed, do not double up the next day.,Common side effects include flushing, itching, and tingling; report severe or persistent effects.,Your doctor will monitor blood glucose, uric acid, and liver function regularly.,Do not substitute with other niacin preparations without doctor approval.
Take this medication at bedtime with a low-fat snack to help reduce flushing and stomach upset.,Flushing, warmth, or tingling may occur, especially after starting or increasing the dose; taking aspirin 30 minutes before the dose can help.,Avoid alcohol and hot beverages near the time you take this medication as they can worsen flushing.,Report any unexplained muscle pain, tenderness, or weakness to your doctor, especially if accompanied by fever or malaise.,Regular blood tests to monitor liver function and blood sugar are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIASPAN vs NICOLAR, answered by our medical review team.
NIASPAN is a Antilipemic agent that works by Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL, and increases HDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and reducing hepatic triglyceride synthesis. It also decreases the catabolism of HDL apolipoproteins A-I and A-II.. NICOLAR is a Antilipemic agent that works by Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and decreasing free fatty acid mobilization from adipose tissue via activation of GPR109A (HM74A) receptor, leading to reduced triglyceride and LDL cholesterol synthesis. It also raises HDL cholesterol by decreasing hepatic clearance of apo A-I.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIASPAN and NICOLAR depend on the specific clinical indication. These are both Antilipemic agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIASPAN is: Starting dose: 500 mg orally once daily at bedtime; after 4 weeks, increase to 1000 mg once daily; then titrate to maintenance dose of 1500-2000 mg once daily; maximum dose: 2000 mg/day.. The standard adult dose of NICOLAR is: NICOLAR (niacin extended-release) is typically initiated at 500 mg orally once daily at bedtime, after a low-fat snack. The dose is increased by 500 mg every 4 weeks as tolerated, up to a maximum of 2000 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIASPAN and NICOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIASPAN is classified as Category C. Niacin (NIASPAN) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects at high doses, but there are no adequate and well-controlled studies in pregna. NICOLAR is classified as Category C. NICOLAR (niacin) is classified as FDA Pregnancy Category C. Adverse effects have been observed in animal reproduction studies, but no adequate human studies exist. First trimester:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.